Analyst Consensus ?
ConsensusHold22 ratings
Bullish1045.5%
Neutral1150.0%
Bearish14.5%
DaVita Inc. · DVA · FY2024 Q3 · Calendar Q4 2024
DaVita Holds Guidance as Supply and Policy Risks Persist
DaVita's operating trajectory remained supported by efficiency initiatives, integrated kidney care improvements, potential CMS-related reimbursement benefits, and international expansion. The case was balanced by supply disruption, mortality-related volume pressure, regulatory execution, and higher interest expense; management maintained full-year guidance rather than raising it.
Reported After market closeNYSEHealthcare
$11.74B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.59
Consensus $2.72
EPS surprise
-4.8%
Reported versus consensus
Reported revenue
$3.26B
Consensus $3.27B
Revenue surprise
-0.1%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-10.8%
Event window
SPY move
-0.3%
Same window
Abnormal move
-10.5%
Stock minus SPY
Volume
5.0×
Versus trailing sessions
Subsequent drift
+17.3%
Up to 20 sessions
DVASPY benchmark
Ask FN2 about DVA FY2024 Q3
Transcript, numbers and history already loaded
Why did DVA fall 10.8% after missing EPS estimates in FY2024 Q3?What changed in DVA's guidance and outlook in FY2024 Q3?Give me the bull and bear case for DVA after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The quarter added detail on Baxter-related supply disruption, including a temporary pause in new peritoneal-dialysis starts and an expected return toward normal supply by Q1 2025. Management also described limited hurricane impact in Q3 with a $10 million to $20 million operating-income headwind expected in Q4, while reaffirming full-year guidance.
Guidance delta
Management maintained full-year 2024 operating-income, EPS, and free-cash-flow guidance.
Key takeaways
- Q3 adjusted operating income was $535 million and adjusted EPS was $2.59, according to the supplied analysis.
- Management said hurricane effects were limited in Q3 but expected a $10 million to $20 million operating-income impact in Q4.
- Baxter-related supply constraints temporarily paused new peritoneal-dialysis starts; normalization was expected by Q1 2025.
- Management identified the CMS oral-drug bundle as a potential patient-access and reimbursement tailwind.
- International expansion and operating efficiencies remained part of the growth plan.
Management priorities
- Resume new peritoneal-dialysis starts as supply conditions improve.
- Implement CMS 2025 final-rule changes.
- Pursue international growth through acquisitions.
- Continue capital allocation to share repurchases and strategic investments.
Follow DVA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$184.03Current
$81Low
$191.58Average
$270High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Aug 7, 2026 |
| TD Cowen | Buy | Hold | Upgrade | Aug 7, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Aug 5, 2026 |
| UBS | Buy | Buy | Maintain | Jul 10, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | May 6, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Sep 10, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | May 15, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 23, 2023 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 29, 2021 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 6, 2020 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 24, 2020 |
| JP Morgan | Neutral | Neutral | Maintain | Dec 20, 2019 |
| Raymond James | Market Perform | Outperform | Downgrade | Nov 7, 2019 |
| Baird | Neutral | Neutral | Maintain | Nov 6, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Sep 11, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 4, 2018 |
| Citigroup | Buy | Neutral | Upgrade | Dec 11, 2017 |
| Jefferies | Hold | Buy | Downgrade | Jun 26, 2017 |
| Keybanc | Hold | Buy | Downgrade | Sep 17, 2014 |
| Atlantic Equities | Overweight | Overweight | Maintain | Oct 10, 2013 |
| Feltl & Co. | Buy | Buy | Maintain | Oct 31, 2012 |
| Bank oferica | Buy | Buy | Maintain | Apr 5, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $184.03. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $215 | $179.92 | +16.8% | Aug 7, 2026 |
| Raymond James | Analyst unavailable | $220 | $180.67 | +19.5% | Aug 7, 2026 |
| Oppenheimer | Analyst unavailable | $220 | $180.67 | +19.5% | Aug 7, 2026 |
| Deutsche Bank | Pito Chickering | $265 | $185.52 | +44.0% | Aug 5, 2026 |
| Barclays | Andrew Mok | $224 | $227.99 | +21.7% | Aug 5, 2026 |
| Truist Financial | Analyst unavailable | $250 | $235.58 | +35.8% | Jul 14, 2026 |
| UBS | Analyst unavailable | $270 | $229.48 | +46.7% | Jul 10, 2026 |
| Barclays | Analyst unavailable | $218 | $234.31 | +18.5% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $205 | $194.38 | +11.4% | May 8, 2026 |
| Barclays | Andrew Mok | $194 | $193.88 | +5.4% | May 7, 2026 |
| Deutsche Bank | Pito Chickering | $220 | $157.04 | +19.5% | May 6, 2026 |
| Truist Financial | Analyst unavailable | $158 | $144.42 | -14.1% | Feb 5, 2026 |
| UBS | Analyst unavailable | $190 | $134.73 | +3.2% | Feb 4, 2026 |
| Barclays | Analyst unavailable | $158 | $111.19 | -14.1% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $143 | $126.56 | -22.3% | Oct 30, 2025 |
| Truist Financial | David MacDonald | $140 | $123.36 | -23.9% | Oct 14, 2025 |
| Barclays | Andrew Mok | $149 | $127.89 | -19.0% | Oct 9, 2025 |
| Truist Financial | David MacDonald | $148 | $129.54 | -19.6% | Aug 8, 2025 |
| Bernstein | Lisa Bedell Clive | $184 | $142.4 | -0.0% | Feb 21, 2025 |
| Bank of America Securities | Kevin Fischbeck | $145 | $133.53 | -21.2% | Aug 7, 2024 |
| Barclays | Andrew Mok | $150 | $134.45 | -18.5% | May 6, 2024 |
| Barclays | Sarah James | $81 | $70.54 | -56.0% | Oct 31, 2022 |
| UBS | Andrew Mok | $117 | $93.1 | -36.4% | Aug 19, 2022 |
| Truist Financial | David MacDonald | $90 | $79.44 | -51.1% | Jun 28, 2022 |
Track every rating change on DVA the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationDaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities.…
Historical context
All DVA earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
Latest beats and misses
Who reports nextBeat on EPS
- VZFY2026 Q3 · October 26, 2026+3.1% EPS-3.5% move
- CXFY2026 Q3 · October 26, 2026+12.0% EPS-0.1% move
- CDNSFY2026 Q3 · October 26, 2026+2.9% EPS+1.8% move
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
Missed on EPS
- KOFFY2026 Q3 · October 26, 2026-9.0% EPS-1.9% move
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
Get the DVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-27T06:30:44.226137+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T06:30:44.222291+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.